Quantum BioPharma Selects Allucent as CRO for Phase 2 Lucid-MS Trial

• Quantum BioPharma has signed a binding letter of intent with CRO Allucent to support a Phase 2 clinical trial of Lucid-21-302 for multiple sclerosis.

• The agreement is intended to advance clinical development and support execution of the planned Phase 2 study. 

Quantum BioPharma Ltd. announced it has signed a binding letter of intent with contract research organization (CRO) Allucent to support a planned Phase 2 clinical trial of Lucid-21-302 (Lucid-MS) for multiple sclerosis. The agreement represents a step forward in the company’s clinical development strategy as it advances its lead therapeutic candidate into mid-stage development.

Lucid-21-302 is a proprietary compound being developed to address demyelination associated with multiple sclerosis. The company indicated that the Phase 2 study will build on previously completed Phase 1 safety and tolerability work and is intended to further evaluate the therapy’s clinical potential. The partnership with Allucent is expected to support key aspects of trial planning, regulatory alignment, and operational delivery.

According to the announcement, Allucent will provide global clinical development expertise, including clinical operations, regulatory guidance, and execution support. The collaboration is designed to help streamline study startup timelines and improve coordination across the clinical development process as Quantum BioPharma advances its multiple sclerosis program.

The agreement forms part of Quantum BioPharma’s broader strategy to expand clinical development capabilities and accelerate advancement of its pipeline. The company focuses on therapies targeting neurodegenerative and metabolic disorders, with Lucid-MS representing a core asset within its development portfolio. The CRO collaboration is expected to strengthen operational infrastructure as the company progresses into Phase 2 clinical evaluation.

“Engaging Allucent represents an important step forward as we advance Lucid-21-302 into Phase 2 clinical development. Their global clinical expertise and operational capabilities are expected to support efficient execution of our clinical program.”

Zeeshan Saeed, Founder and Chief Executive Officer of Quantum BioPharma